AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Kim Julie So-Young sold $1.5M of TAK

Kim Julie So-Young (President and CEO) sold 89,090 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($1.52M total) on 2026-08-10.

Original reporting
SEC EDGAR · Kim Julie So-Young
Published Aug 13, 2026, 1:27 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change earnings, guidance, or risk materially.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which can increase scrutiny, but the disclosed size ($1.52M) is still modest relative to typical large-cap valuation and lacks accompanying operational news.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-12 after the 2026-08-10 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Takeda CEO Kim Julie So-Young sold 89,090 shares in an open-market transaction valued at $1.52M, per a fresh Form 4 filing.

Expected impact

Likely minimal near-term price impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, and the text specifies an open-market sale with no 10b5-1 plan, but it does not provide new company performance, guidance, or regulatory/contract developments.

Market effects

Sector

No sector-level implications are disclosed; this is company-specific insider trading reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated versus fundamentals.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the Form 4 issuer.

  • insider
    Kim Julie So-Young

    President and CEO and reporting insider who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min